期刊文献+

夏枯草硫酸多糖对肝癌血管生成的作用及机制研究 被引量:27

Effect and mechanism of Prunella vulgaris sulfated polysaccharide on angiogenesis in hepatocellular carcinoma
在线阅读 下载PDF
导出
摘要 目的:观察夏枯草硫酸多糖(PVSP)对肝癌细胞中血管生成因子bFGF,VEGF和IL-8蛋白分泌及肝癌血管生成的影响。方法:ELISA法观察PVSP和香菇多糖(LNT,不含硫酸基,阴性对照)对bFGF、VEGF和IL-8在肝癌细胞中的分泌情况影响;免疫组化法观察PVSP和LNT以及PBS空白对照对肝癌组织微血管密度的影响。结果:同PBS空白对照相比,200μg/mL的PVSP抑制bFGF的分泌(P<0.01),而LNT对bFGF表达无影响。各剂量组的PVSP和LNT对VEGF、IL-8的分泌均无影响。200 mg/kgPVSP能够减少肿瘤组织块中的微血管密度(P=0.03),而LNT 10 mg/kg对肿瘤组织中微血管密度无影响。结论:PVSP对bFGF分泌的抑制作用是其抑制肝癌血管生成的一个可能原因。 Objective:A study was conducted to investigate the effect of Prunella vulgaris sulfated polysaccharide (PVSP) on the expression of angiogenic growth factors (bFGF, VEGF, and IL-8) and angiogenesis in hepatocellular carcinoma. Methods:ELISA as-say was used to observe the effects of PVSP and the negative control drug Lentinan (LNT, non-sulfate radical drug) on secretions of the angiogenic growth factors, namely, bFGF, VEGF, and IL-8, in HepG2 cells in vitro. In an in vivo experiment, the microvessel density in hepatocellular carcinoma tissue sections treated with PVSP and LNT was calculated, analyzed, and compared with the microvessel den-sity in the phosphate-buffered saline (PBS) control. Results:Compared with the PBS control group, PVSP at 200μg/mL inhibited bF-GF secretion (P〈0.01), whereas LNT failed to affect bFGF secretion. Neither PVSP nor LNT affected the secretions of VEGF and IL-8. In vivo results showed that PVSP at 200 mg/kg reduced the microvessel density in tumor tissue sections (P=0.03), whereas LNT at 10 mg/kg failed to affect microvessel density. Conclusion:Inhibition of bFGF secretion is a probable mechanism underlying the preven-tive effect of PVSP on hepatocellular carcinoma angiogenesis.
出处 《中国肿瘤临床》 CAS CSCD 北大核心 2014年第12期758-761,共4页 Chinese Journal of Clinical Oncology
基金 国家自然科学基金资助项目(编号:81173376) 天津市应用基础及前沿技术研究计划(编号:NCET-11-1068)资助~~
关键词 夏枯草硫酸多糖 香菇多糖 血管生成 肝癌 微血管密度 BFGF prunella vulgaris sulfated polysaccharide Lentinan angiogenesis hepatocellular carcinoma microvessel density bFGF
  • 相关文献

参考文献15

  • 1Burri PH,Hlushchuk R, Djonov V. Intussusceptive angiogenesis: its emergence, its characteristics, and its significance[J]. Dev Dyn, 2004, 231 (3) :474-488.
  • 2Benazzi C, AI-Dissi A, Chau CH, et al. Angiogenesis in spontaneous tumors and implications for comparative tumor biology[J]. Scientific World Journal, 2014, 2014: 919570. doi: 10.1155/2014/919570.
  • 3Zhang SX, Zhu C, Ba Y, et al. Gekko-sulfated glycopeptide inhib- its minor angiogenesis by targeting basic fibroblast growth factor[J]. J Biol Chem, 2012, 287(16):13206-13215.
  • 4Ribatti D. Cancer stem cells and tumor angiogenesis[J]. Cancer Lett, 2012, 321(1):13-17.
  • 5Choudhary S, Hegde P, PruittJR, et al. Macrophage migratory in- hibitory factor promotes bladder cancer progression via increasing proliferation and angiogenesis[J]. Carcinogenesis, 2013, 34(12): 2891-2899.
  • 6Mohammadi M, Olsen SK, Ibrahimi OA. Structural basis for fibro- blast growth factor receptor activation[J]. Cytokine Growth Factor Rev, 2005, 16(2):107-137.
  • 7ChoiJH, Han EH, Hwang YP, et al. Suppression of PMA-induced tumor cell invasion and metastasis by aqueous extract isolated from Prunella vulgarisvia the inhibition of NF-kappaB-dependent MMP-9 expression[J]. Food Chem Toxicol, 2010, 48(2):564-571.
  • 8Ina K, Kataoka T, Anclo T. The use of lentinan for treating gastric cancer[J]. Anticancer Agents Med Chem, 2013, 13(5):681-688.
  • 9Yang JD, Roberts LR. Hepatocellular carcinoma: A global view[J]. Nat Rev Gastroenterol Hepatol, 2010, 7(8):448-458.
  • 10谢勇,龙光辉,刘晓平,刘吉奎,周晓初,钟立明.5-FU经不同途径区域化疗影响大鼠肝癌血管生成的研究[J].临床医药实践,2009,18(3Z):1448-1450. 被引量:1

二级参考文献41

  • 1Jenab-Wolcott J, Giantonio BJ. Bevacizumab: Current indications and future development for management of solid tumors [J]. Expert Opin Biol Ther, 2009, 9 (4):507.
  • 2Jain R K, et al. Lessons from phase Ⅲ clinical trials on anti-VEGF therapy for cancer [J]. Nat Clin Pratt Oncol, 2006, 3 : 24.
  • 3Chase JL. Clinical use of anti-vascular endothelial growth factor monoclonal antibodies in metastatic colorectal cancer [ J ]. Pharmacotherapy, 2008, 28 ( 11 Pt 2) : S23.
  • 4Willett CG, Duda DG, di Tomaso E, et al. Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: A multidisciplinary phase Ⅱ study [J]. J Clin Oncol, 2009, 27(18) :3020.
  • 5Willett CG, Kozin SV, Duda DG. et al. Combined VEGF- targeted therapy and radiotherapy for rectal cancer: Theory and clinical practice [J]. Semin Oncol, 2006, 33 (5 Suppl 10): s35.
  • 6Ellis LM. Mechanisms of action of bevacizumab as a component of therapy for metastatic colorectal cancer [J]. Semin Oncol, 2006, 33:S1.
  • 7Sandier A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer [ J ]. N Engl J Med, 2006, 355 : 2542.
  • 8Motzer RJ, et al. Sunitinib versus interferon α in metastatic renal-cell carcinoma [J]. N Engl J Med, 2007, 356: 115.
  • 9Escudier B, et al. Sorafenib in advanced clear-cell renal-cell carcinoma [J]. N Engl J Med, 2007, 356 : 125.
  • 10Zhu AX. Development of sorafenib and other molecularly targeted agents in hepatocellular carcinoma [J]. Cancer, 2008, 112:250.

共引文献7

同被引文献538

引证文献27

二级引证文献150

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部